Ring 1
Ring 2
Ring 3
Ring 4

Clene Nanomedicine

Financing Rounds

  • Series D+
  • Public
Round Led by Symbiosis
Round Led by Symbiosis

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure, an underlying driver of many neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

clene View Website


  • Other


  • Neurology

Development Status

  • Phase 3+